New avenues for Parkinson's disease therapeutics: disease-modifying strategies based on the gut microbiota
Open accessThe DOI matches its Crossref record; 365 of the 366 references it cites were found in a registry or an index.
Abstract
Parkinson's disease (PD) is a multifactorial neurodegenerative disorder that currently affects 1% of the population over the age of 60 years, and for which no disease-modifying treatments exist. Neurodegeneration and neuropathology in different brain areas are manifested as both motor and non-motor symptoms in patients. Recent interest in the gut-brain axis has led to increasing research into the gut microbiota changes in PD patients and their impact on disease pathophysiology. As evidence is piling up on the effects of gut microbiota in disease development and progression, another front of action has opened up in relation to the potential usage of microbiota-based therapeutic strategies in treating gastrointestinal alterations and possibly also motor symptoms in PD. This review provides status on the different strategies that are in the front line (i.e., antibiotics; probiotics; prebiotics; synbiotics; dietary interventions; fecal microbiota transplantation, live biotherapeutic products), and discusses the opportunities and challenges the field of microbiome research in PD is facing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It appears that the Parkinson's disease-related gut dysbiosis is associated with the imbalance of SCFAs-producing bacteria (Prevotellaceae, Faecalibacterium, and Ruminococcaceae), bacteria that participate in lipid metabolism (e.g., Christensenellaceae) and those controlling gut permeability (e.g., Verrucomicrobiaceae, Akkermansia) [418,419,445].”
From The Role of Microbiota-Gut-Brain Axis in Neuropsychiatric and Neurological Disorders (2021) · cites this paper as [445]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“An important observation is that human gut microbiota metabolizes levodopa and thereby may affect its bioavailability and efficacy.”
From The Role of Microbiota-Gut-Brain Axis in Neuropsychiatric and Neurological Disorders (2021) · cites this paper as [445]
In the citing paper
“Identification of bacteria that metabolize levodopa to dopamine (Enterococcus faecalis) and dopamine to m-tyramine (Eggerthella lenta) [445]”
From The Role of Microbiota-Gut-Brain Axis in Neuropsychiatric and Neurological Disorders (2021) · cites this paper as [445]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Tamtaji, O. R., Taghizadeh, M., Daneshvar Kakhaki, R., Kouchaki, E., Bahmani, F., Borzabadi, S., Oryan, S., Mafi, A., & Asemi, Z. (2019) · Clinical Nutrition · doi:10.1016/j.clnu.2018.05.018 · Cited by 398 · cited 2×
“Lactobacillus acidophilus, Bifidobacterium bifigum, Lactobacillus reuteri and Lactobacillus fermentum (capsules) 8 × 109 CFU 1X a day for 12 weeks PD patients • Decreased MDS-UPDRS scores [253]”
BackgroundMethodRetractedRetracted: Gut Microbiome Signatures of Risk and Prodromal Markers of Parkinson Disease
Heinzel, S., Aho, V. T. E., Suenkel, U., von Thaler, A., Schulte, C., Deuschle, C., Paulin, L., Hantunen, S., Brockmann, K., Eschweiler, G. W., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25788 · Cited by 95
RetractedHill (2014) · doi:10.1038/nrgastro.2014.66 · Cited by 9,592 · cited 1×
“Probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit to the host [236].”
BackgroundHuman gut microbiome viewed across age and geography
Yatsunenko, T., Rey, F. E., Manary, M. J., Trehan, I., Dominguez-Bello, M. G., Contreras, M., Magris, M., Hidalgo, G., Baldassano, R. N., Anokhin, A. P., et al. (2012) · Nature · doi:10.1038/nature11053 · Cited by 7,815
Dietary Modulation of the Human Colonic Microbiota: Introducing the Concept of Prebiotics
Gibson, G. R., & Roberfroid, M. B. (1995) · The Journal of Nutrition · doi:10.1093/jn/125.6.1401 · Cited by 7,667
Enterotypes of the human gut microbiome
MetaHIT Consortium (additional members), Arumugam, M., Raes, J., Pelletier, E., Le Paslier, D., Yamada, T., Mende, D. R., Fernandes, G. R., Tap, J., Bruls, T., et al. (2011) · Nature · doi:10.1038/nature09944 · Cited by 7,548
Molecular Mechanisms of Stress-Responsive Changes in Collagen and Elastin Networks in Skin
Aziz, J., Shezali, H., Radzi, Z., Yahya, N. A., Abu Kassim, N. H., Czernuszka, J., & Rahman, M. T. (2016) · Skin Pharmacology and Physiology · doi:10.1159/000447017 · Cited by 7,323
From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites
Koh, A., De Vadder, F., Kovatcheva-Datchary, P., & Bäckhed, F. (2016) · Cell · doi:10.1016/j.cell.2016.05.041 · Cited by 7,070 · cited 1×
“Moreover, they induce the expression of anti-inflammatory cytokines and suppress the expression of the pro-inflamatory ones [128,129].”
BackgroundInflamm‐aging: An Evolutionary Perspective on Immunosenescence
FRANCESCHI, C., BONAFÈ, M., VALENSIN, S., OLIVIERI, F., DE LUCA, M., OTTAVIANI, E., & DE BENEDICTIS, G. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06651.x · Cited by 5,358 · cited 1×
“This contributes to the deterioration of the neuro-immune system in a process called immunosenescence [157] and is directly related with inflammaging [158,159].”
BackgroundMind-altering microorganisms: the impact of the gut microbiota on brain and behaviour
Cryan, J. F., & Dinan, T. G. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3346 · Cited by 4,572
Cited by
The Role of Microbiota-Gut-Brain Axis in Neuropsychiatric and Neurological Disorders
Socała, K., Doboszewska, U., Szopa, A., Serefko, A., Włodarczyk, M., Zielińska, A., Poleszak, E., Fichna, J., & Wlaź, P. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105840 · Cited by 857
A Comprehensive Review on the Role of the Gut Microbiome in Human Neurological Disorders
Sorboni, S. G., Moghaddam, H. S., Jafarzadeh-Esfehani, R., & Soleimanpour, S. (2022) · Clinical Microbiology Reviews · doi:10.1128/cmr.00338-20 · Cited by 522
Therapeutic Benefits and Dietary Restrictions of Fiber Intake: A State of the Art Review
Ioniță-Mîndrican, C.-B., Ziani, K., Mititelu, M., Oprea, E., Neacșu, S. M., Moroșan, E., Dumitrescu, D.-E., Roșca, A. C., Drăgănescu, D., & Negrei, C. (2022) · Nutrients · doi:10.3390/nu14132641 · Cited by 251
Parkinson’s disease and gut microbiota: from clinical to mechanistic and therapeutic studies
Zhang, X., Tang, B., & Guo, J. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00392-8 · Cited by 187
“Microbial therapy can improve the clinical manifestations of PD [43].”
BackgroundGut Microbiota: A Novel Therapeutic Target for Parkinson’s Disease
Zhu, M., Liu, X., Ye, Y., Yan, X., Cheng, Y., Zhao, L., Chen, F., & Ling, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.937555 · Cited by 177
Jonscher, K. R., Chowanadisai, W., & Rucker, R. B. (2021) · Biomolecules · doi:10.3390/biom11101441 · Cited by 153
Gupta, R., Kumari, S., Senapati, A., Ambasta, R. K., & Kumar, P. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102013 · Cited by 134
Fecal microbiota transplant as a potential treatment for Parkinson's disease – A case series
Segal, A., Zlotnik, Y., Moyal-Atias, K., Abuhasira, R., & Ifergane, G. (2021) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2021.106791 · Cited by 124
Varesi, A., Campagnoli, L. I. M., Fahmideh, F., Pierella, E., Romeo, M., Ricevuti, G., Nicoletta, M., Chirumbolo, S., & Pascale, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012289 · Cited by 88
Probiotics for Neurodegenerative Diseases: A Systemic Review
Ojha, S., Patil, N., Jain, M., Kole, C., & Kaushik, P. (2023) · Microorganisms · doi:10.3390/microorganisms11041083 · Cited by 88
“Another 2019 research demonstrates that the major pro- and anti-inflammatory cytokines, as well as ROS, are produced by Lactobacillus and Bifidobacterium genus when peripheral blood mononuclear cells (PBMCs) isolated from people with Parkinson’s disease (PD) are compared to healthy participants [137].”
BackgroundMediterranean Diet and Parkinson’s Disease
Bisaglia, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010042 · Cited by 83
“There are many ways through which ω3-PUFAs may impact the brain and be beneficial in the prevention and/or treatment of PD, including their antioxidant and anti-inflammatory properties, and different mechanisms of action behind their anti-inflammatory activity have been proposed [15,19,30].”
BackgroundInfluentialThe brain-gut-microbiota axis in the treatment of neurologic and psychiatric disorders
Naufel, M. F., Truzzi, G., Ferreira, C. M., & Coelho, F. M. S. (2023) · Arquivos de Neuro-Psiquiatria · doi:10.1055/s-0043-1767818 · Cited by 86
Layunta, E., Buey, B., Mesonero, J. E., & Latorre, E. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.748254 · Cited by 72
Inflammatory microbes and genes as potential biomarkers of Parkinson’s disease
Nie, S., Wang, J., Deng, Y., Ye, Z., & Ge, Y. (2022) · npj Biofilms and Microbiomes · doi:10.1038/s41522-022-00367-z · Cited by 72
A new paradigm for a new simple chemical: butyrate & immune regulation
Dang, G., Wu, W., Zhang, H., & Everaert, N. (2021) · Food & Function · doi:10.1039/d1fo02116h · Cited by 74
Gut-brain axis and neurodegeneration: mechanisms and therapeutic potentials
Park, K. J., & Gao, Y. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1481390 · Cited by 71
Zhang, Y., Xu, S., Qian, Y., Mo, C., Ai, P., Yang, X., & Xiao, Q. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1099018 · Cited by 58
“The gut microbiota dysbiosis may be related to the pathogenesis of PD, and gut microbiota remodeling could exert beneficial effects (Liu et al., 2020; Lorente-picón and Laguna, 2021).”
BackgroundChen, Y., Rudolph, S., Longo, B. N., de Pace, F., Roh, T. T., Condruti, R., Gee, M. M., Watnick, P. I., & Kaplan, D. L. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202200447 · Cited by 43
Ketogenic diet inhibits glioma progression by promoting gut microbiota-derived butyrate production
Chen, M., He, Y., Dong, X., Liu, H.-F., Yan, Z., Lu, X.-L., Miao, Q.-Q., Zhao, Q., Zhang, H., Luo, L., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.09.002 · Cited by 39
Current understanding of the human microbiome in glioma
Liang, J., Li, T., Zhao, J., Wang, C., & Sun, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.781741 · Cited by 40
Gut brain axis: an insight into microbiota role in Parkinson’s disease
Moustafa, S. A., Abdou, S. M., Dawood, A. S., Azar, J., Elmorsy, E. M., Rizk, N., & Salama, M. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00808-2 · Cited by 37
Pathways to healing: Plants with therapeutic potential for neurodegenerative diseases
Tyler, S. E. B., & Tyler, L. D. K. (2023) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2023.01.006 · Cited by 37
“Microbial endotoxins from gut microbiota may also contribute to pathologies in PD (Tufekci et al., 2011) (Lorente-Pic ´ on and Laguna, 2021), ALS (Zhang et al., 2009) and AD (Leblhuber et al., 2021).”
Gut microbiota, pathogenic proteins and neurodegenerative diseases
Wei, W., Wang, S., Xu, C., Zhou, X., Lian, X., He, L., & Li, K. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.959856 · Cited by 33
DNA Methylation Signature of Aging: Potential Impact on the Pathogenesis of Parkinson’s Disease
Yazar, V., Dawson, V. L., Dawson, T. M., & Kang, S.-U. (2023) · Journal of Parkinson s Disease · doi:10.3233/jpd-223517 · Cited by 34
Parkinson’s Disease: A Prionopathy?
Vascellari, S., & Manzin, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158022 · Cited by 36
“Several studies underline that in different experimental models of PD, in addition to the antimicrobial activity, anti-inflammatory, neuroprotective, and anti-aggregation effects have been shown [136].”
BackgroundPeng, H.-R., Yu, S., Zhang, Y., Yin, Y., & Zhou, J. (2022) · Neuroscience Bulletin · doi:10.1007/s12264-022-00848-3 · Cited by 21
“It has been shown that the relative abundance of the genus Klebsiella and Staphylococci is decreased in older people [27] and the genus Klebsiella is also decreased in subjects with PD [28].”
BackgroundKerstens, R., & Joyce, P. M. (2024) · Biomedicines · doi:10.3390/biomedicines12081738 · Cited by 20
Cuevas-Carbonell, S. G., Vásquez-Celaya, L., García-López, D., Granados-Patrón, D., García‐Miss, M. D. R., Álvarez-Cervera, F. J., Mut-Martín, M., Parra, I., Mendieta, L., Salgado, H., et al. (2022) · Neuroscience · doi:10.1016/j.neuroscience.2022.11.004 · Cited by 19
The role of the gut microbiota in neurodegenerative diseases targeting metabolism
Fu, Y., Gu, Z., Cao, H., Zuo, C., Huang, Y., Song, Y., Jiang, Y., & Wang, F. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1432659 · Cited by 18
Liu, Y., Liu, X., Ye, Q., Wang, Y., Zhang, J., Lin, S., Wang, G., Yang, X., Zhang, J., Chen, S., et al. (2022) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.2c06429 · Cited by 16
Gut Microbiome and Its Role in Parkinson's Disease
Suresh, S. B., Malireddi, A., Abera, M. B., Noor, K., Ansar, M., Boddeti, S., & Nath, T. S. (2024) · Cureus · doi:10.7759/cureus.73150 · Cited by 29
Techaniyom, P., Korsirikoon, C., Rungruang, T., Pakaprot, N., Prombutara, P., Mukda, S., Kettawan, A., & Kettawan, A. (2024) · Food Science & Nutrition · doi:10.1002/fsn3.4265 · Cited by 14
Ginsenosides can target brain-derived neurotrophic factor to improve Parkinson's disease
Ding, Y., Botchway, B. O. A., Zhang, Y., & Liu, X. (2023) · Food & Function · doi:10.1039/d2fo03484k · Cited by 13
The Role of Probiotics In Tissue Engineering And Regenerative Medicine
Golchin, A., Ranjbarvan, P., Parviz, S., Shokati, A., Naderi, R., Rasmi, Y., Kiani, S., Moradi, F., Heidari, F., Saltanatpour, Z., et al. (2023) · Regenerative Medicine · doi:10.2217/rme-2022-0209 · Cited by 15
Calprotectin, Biomarker of Depression in Patients with Inflammatory Bowel Disease?
Iordache, M. M., Belu, A. M., Vlad, S. E., Aivaz, K.-A., Dumitru, A., Tocia, C., & Dumitru, E. (2023) · Medicina · doi:10.3390/medicina59071240 · Cited by 12
“Lorente-Picón suggested the treatment of motor symptoms through microbiota-based therapeutic strategies [52].”
BackgroundTuning gut microbiota by advanced nanotechnology
Qi, Y., Wang, Y., Wang, X., Zheng, H., & Lu, Y. (2025) · Materials Futures · doi:10.1088/2752-5724/ada62b · Cited by 16
“Antibiotics are one of the most effective means of modulating gut microbiota for a wide range of diseases, such as cancer, alcoholic liver disease, and Parkinson’s disease [59–61].”
Wang, Y., Pu, Z., Zhang, Y., Du, Z., Guo, Z., & Bai, Q. (2022) · Behavioural Brain Research · doi:10.1016/j.bbr.2022.114240 · Cited by 14
Synergistic Welfare of Synbiotic Nutraceuticals on Neurological Function
Bhat, A. A., Gilhotra, R. M., Thapa, R., Subramaniyan, V., Singh, S. K., Yadav, V. K., Dave, P. N., Singla, N., & Gupta, G. (2024) · Springer eBooks · doi:10.1007/978-981-99-5575-6_29 · Cited by 14
Debi, P. R., Barua, H., Ahmmed, M. K., & Bhowmik, S. (2025) · Marine Drugs · doi:10.3390/md23080310 · Cited by 8
“Imbalance or dysbiosis of the intestinal microbiome is associated with functional changes in the CNS, facilitated by microbial metabolites and bidirectional interactions with the nervous, immune, and endocrine system along the gut– brain axis [306,307].”
Contarino, M. F., van Hilten, J. J., & Kuijper, E. J. (2022) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.13621 · Cited by 12
“There are different strategies to modify gut microbiota composition, ranging from dietary interventions(26) to treatment with dietary supplements, antibiotics, or genetically engineered microorganisms.(27) Specific antibiotics may target proinflammatory bacteria, thus exerting an anti-inflammatory, antiapoptotic, and…”
Ageing, Neurodegeneration and the Endocannabinoid System
Fernández‐Ruíz, J., Sagredo, O., Gómez‐Ruíz, M., & de Lago, E. (2025) · Current topics in behavioral neurosciences · doi:10.1007/7854_2025_597 · Cited by 9
Disease modifying therapies for Parkinson's disease: Novel targets
Vijiaratnam, N., & Foltynie, T. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108839 · Cited by 7
New Insights on the Role of Bioactive Food Derivatives in Neurodegeneration and Neuroprotection
Fisette, A., Sergi, D., Breton-Morin, A., Descôteaux, S., & Martinoli, M. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612828666220919085742 · Cited by 6
Effects of a crude extract of Echinops mosulensis on an induced Parkinson’s disease model in mice
Ahmed, A. A., & Kadhim, H. M. (2024) · Pharmacia · doi:10.3897/pharmacia.71.e131570 · Cited by 5
Li, J., Ni, Y., Huang, L., Yu, X., & Zhu, J. (2022) · Acta Cirúrgica Brasileira · doi:10.1590/acb371104 · Cited by 6
Food for thought: probiotic modulation of microglial activity in Parkinson's disease
Kimber, I. K., & Tremblay, M. (2025) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2025.1690507 · Cited by 4
Onaolapo, A. Y., Ojo, F. O., Olofinnade, A. T., Falade, J., Lawal, I. A., & Onaolapo, O. J. (2022) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527321666220903114559 · Cited by 5
Role of Nutraceuticals and Physical Activity in Parkinson's Disease Risk and Lifestyle Management
Wal, P., Vig, H., Wal, A., Rathore, S., Pandey, S. S., Jain, N. K., & Srivastava, A. (2023) · Current Aging Science · doi:10.2174/1874609816666230515121717 · Cited by 5
Chai, J.-Y., Zhang, Y. P., Zhang, Z., Ma, D., Cao, Y.-H., Zhu, S.-R., Yun-zhi, M., Luo, L.-L., Zhan, Y.-L., Fan, Z.-Y., et al. (2026) · Reviews in the Neurosciences · doi:10.1515/revneuro-2026-0041 · Cited by 3
“Recent studies indicate that gut microbiota dysbiosis promotes the spread of α -syn and tau pathology via the brain-gut axis, closely correlating with PD ’ s non-motor symptoms (Lorente-Picón and Laguna 2021).”
Silent Intruders: The Gut Virome in Brain Aging and Cognitive Decline
Silvestro, S., Midiri, A., Biondo, C., Casilli, S., Borrello, L., Zummo, S., & Mancuso, G. (2026) · Pathogens · doi:10.3390/pathogens15020180 · Cited by 2
“This increase is problematic, as it has been observed that PD patients infected with Helicobacter pylori show reduced absorption of L-dopa [84].”
Immunology and microbiome: Implications for motor systems
Mahjoub, Y., & Martino, D. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-323-98818-6.00001-7 · Cited by 2
Ideal Synbiotics: Pharmacokinetic, Pharmacodynamic, and Safety Assessment
Pathak, S., Kim, S., Lynn, G., Martin, N., Thomas, B., Patel, I., Nadar, R. M., Pondugul, S., DeRuiter, J., Dua, K., et al. (2024) · Springer eBooks · doi:10.1007/978-981-99-5575-6_23 · Cited by 2
Fernández‐Ruíz, J., Rodríguez-Cueto, C., García, C., Satta, V., Gómez-Cañas, M., Sagredo, O., de Lago, E., & Gómez-Ruiz, M. (2025) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-443-13908-6.00023-2 · Cited by 1
Burgaz, S., Rodríguez-Carreiro, S., Navarro, E., Lastres‐Becker, I., García-Arencibia, M., Palomo‐Garo, C., Gómez‐Gálvez, Y., Gómez‐Cañas, M., García, C., & Fernández‐Ruíz, J. (2026) · Molecular Neurodegeneration Advances · doi:10.1186/s44477-025-00016-7 · Cited by 1
“However, a major challenge remains the lack of effective disease-modifying therapies, despite extensive research into numerous neuroprotective agents [23–25], even at the clinical level [26], and including cell therapy (transplants of dopamine-producing cells) too [27].”
Aptamer-Loaded Cubosome Lipid Nanoparticles for the Treatment of Tuberculosis
Sarkar, S., Sharma, T. K., Yu, H., Dyett, B., Ball, A. S., Drummond, C. J., Soni, S. K., & Conn, C. E. (2026) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6c04961 · Cited by 1
Gut microbiota as a modulator of HDAC: insights into Alzheimer’s disease treatment
Verma, E., Mishra, S., Chellammal, H. S. J., Khandige, P. S., & Gasmi, A. (2026) · Pharmacological Reports · doi:10.1007/s43440-026-00897-9 · Cited by 1
Role of Gastrointestinal Dysbiosis and Fecal Transplantation in Parkinson’s Disease
Jena, R., Jain, R., Muralidharan, S., Yanamala, V. L., Zubair, Z., Kantamaneni, K., Jalla, K., Renzu, M., & Alfonso, M. (2021) · Cureus · doi:10.7759/cureus.19035 · Cited by 2
“There is also a need to explore the exact mechanism by which FMT restores eubiosis and the exact changes in the gastrointestinal microbiota before and after FMT [38,39].”
BackgroundThe potentially important role of intestinal brain (gut microbiota) in neuropsychiatric health
Petrić, D. (2023) · Microenvironment and Microecology Research · doi:10.53388/mmr2023001
The Scenario of Emerging Gut Microbiome Cross Talks in Brain Aging
Panneerselvam, S., Jayaraman, S., & Rajagopal, P. (2024) · Springer eBooks · doi:10.1007/978-981-99-8803-7_2
O eixo microbiota-intestino-cérebro na doença de Parkinson: revisão integrativa
Mafra, H. T., & de Souza, J. P. P. (2024) · Brazilian Journal of Health Review · doi:10.34119/bjhrv7n4-011
Aguena, M. Y., Ogata, A. C. D. O., Baptista, J. V. D. C. N., Pereira, L. F. S., Ramalho, G. O., Hubner, M. L. R. D. P., Forti, L. K., Senssulini, V. L., de Melo, S. O. S., Meireles, I. S., et al. (2025) · International Journal of Health Science · doi:10.22533/at.ed.159552515015
Future prospective of microbiome-gut brain axis for treatment of CNS disorders
Mane, R., Kashid, S., Mazahir, F., & Yadav, A. K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-21680-0.00019-5
Yuan, X. (2025) · Pharmacognosy Magazine · doi:10.1177/09731296251362609
“Parkinson’s disease (PD) is among the most common neuro-degenerative diseases, following Alzheimer’s disease, impacting 1% of people aged 60 or older (Koziorowski et al., 2021; Lorente-Picón & Laguna, 2021).”
InfluentialThe Aging Gut–Brain Axis: Effects of Dietary Polyphenols and Metal Exposure
Cao, L., Jha, S. K., Gupta, N., Chen, X., Soni, R., Yuan, L., Srivastava, R., & Chen, Z. (2025) · Chronic Diseases and Translational Medicine · doi:10.1002/cdt3.70026 · Cited by 2
Lang, J., & Xiong, Z. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1624315
Urganci, Ü., & Isik, F. (2025) · Analecta Technica Szegedinensia · doi:10.14232/analecta.2025.3-4.48-73
REVIEW OF INTEGRATED APPROACHES FOR THE TREATMENT OF PARKINSON'S DISEASE
Gul, R., & Shakeela, B. (2026) · International Journal of Biology and Biotechnology · doi:10.65014/ijbb.v23i.15
Gut Microbiome Imbalance: The Root Causes of Neurodegeneration?
Konika, T. A., Shamsuzzaman, M., Uddin, M. E., & Kim, J. (2026) · Springer eBooks · doi:10.1007/978-981-95-7494-0_2
Hey, G. E., Kamo, H., Garcia, G. P. R., Hedera, P., & Ramirez‐Zamora, A. (2026) · Journal of Neurology · doi:10.1007/s00415-026-13914-x
“The gut microbiota regulate bidirectional communication between the central and enteric nervous systems [59].”
InfluentialThe role of gut microbiota in Parkinson's disease pharmacotherapy
Wadan, A. S., Hammadeh, B. M., Ahmed, M. A., Maged, A. A., & Ellakwa, D. E. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-54032-5.00002-4
Yu, X., He, J., & Liu, M. (2026) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2026.579117
Metadata
- Authors
- Lorente-Picón, M., & Laguna, A.
- Affiliations
- Neurodegenerative Diseases Research Group, Vall d’Hebron Research Institute (VHIR)-Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Passeig Vall d’Hebron 119-129, 08035 Barcelona, Spain
- Biomedical Research Networking Center on Neurodegenerative Diseases (ES)
- Corresponding author
- Laguna, Ariadna
- Venue
- Biomolecules
- Publisher
- MDPI AG
- Published
- 2021-03-15
- Volume
- 11
- Issue
- 3
- Pages
- 433
- ISSN
- 2218-273X (ISSN-L)
- PMC
- PMC7998286
- OpenAlex
- W3139351167
- Cited by
- 69
- References
- 366
- Citations by year
- 2026: 8 · 2025: 12 · 2024: 10 · 2023: 13 · 2022: 17 · 2021: 9
- FWCI
- 1.57
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Biomolecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- La Caixa Banking Foundation (LCF/BQ/PR19/11700005)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Keywords
- Parkinson's disease, gut microbiota, gut-brain axis, disease-modifying therapy, probiotics, prebiotics, synbiotics, fecal microbiota transplantation, live biotherapeutic products, antibiotics, dietary intervention, motor symptoms, neurodegeneration
- MeSH terms
- Gastrointestinal Microbiome, Fecal Microbiota Transplantation, Brain, Humans, Parkinson Disease, Phylogeny, Neuroprotective Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.